Sign in
CompletedPhase 3

IPAD Trial

Key facts

Who runs it
Universitair Medisch Centrum Utrecht
Where
Netherlands3 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
100 people enrolled
Started
12 Jul 2024
Ended
31 Mar 2026
Type of study
Interventional
Record updated
18 March 2026

Who can take part

Age
Up to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age 8-60 years
  • Diagnosis of Primary Antibody Deficiency / Common Variable Immunodeficiency Disorder (see Appendix I protocol)
  • Indication for immunoglobulin replacement therapy and/or treated with immunoglobulin replacement therapy
  • Current IgG dosing 0.25 - 0.6 gr / kg / 3-4 weeks
  • Receiving treatment and follow-up for PAD by a physician in one of the participating centers
  • Written informed consent

Who cannot take part

  • Diagnosis of Combined Immunodeficiency (CID) disease at onset of study (see Appendix 1). Explanation: Combined Immunodeficiency is featured by the occurrence of more viral infections and reactivations and thus less comparable to PAD
  • Severe pulmonary disease, determined by an independent radiologist: a. Baseline AD score > 7 and/or ILD score > 5, in combination with: i. Saccular bronchiectasis on CT scan, or; ii. Clinical diagnosis of severe respiratory insufficiency ( (defined as: saturations in room air <92%, and/ or oxygen dependency). b. Baseline pulmonary function (FEV1 and FVC) <70% expected for age and body weight / length)
  • Active smoker

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Influencing Progression of Airway Disease in Primary Antibody Deficiency
Record updated
18 March 2026